Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 431 participants.

Also called NCT01494987

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 431 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01494987
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Malaysia, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Thailand, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01494987. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-08 (actual). Results posted on 2014-09-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ranolazine
Intervention (Drug)
Placebo
Intervention (Drug)
Glimepiride
Intervention (Behavioral)
Diet
Intervention (Behavioral)
Exercise
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01494987
Content hash
5adc1e02bb354d26dc0b5b848e71ec17ba163214f26a8d24f8a864758dbbdc7d